Management of Patients with Bilateral Multi-focal Colorectal Liver Metastasis: Two-Stage Approach
Executive Summary
Surgical resection remains the most effective treatment for colorectal liver metastases (CRLM), offering a 5-year survival rate of approximately 60%. However, fewer than 25% of patients are initially deemed resectable, primarily due to the challenge of removing all tumor deposits while maintaining an adequate future liver remnant (FLR). The "two-stage hepatectomy" is a curative strategy involving planned, sequential resections designed to allow for liver hypertrophy between operations.
While this approach enables the treatment of advanced disease, it faces a significant "dropout" rate of 20–30%—patients who cannot proceed to the second stage due to tumor progression or insufficient liver growth. Successful outcomes depend on meticulous preoperative staging using high-quality imaging (MRI and CT), intraoperative ultrasound (IOUS), and the calculation of kinetic growth rates (KGR) to ensure the safety of major resections. Compared to alternative strategies like ALPPS or one-stage RFA-assisted resections, the two-stage approach is considered the most reliable and standardized method for managing complex bilateral CRLM.
Overview of the Two-Stage Strategy
The two-stage hepatectomy, initially conceived by Adam et al., addresses the morphological challenges of multiple, bilobar metastases where a single major resection would leave an insufficient FLR, risking postoperative liver insufficiency.
The Two-Stage Sequence
First Stage: The primary goal is to "clean" one hemiliver (usually the planned FLR) through limited, parenchymal-sparing resections. If the patient has synchronous metastases, the primary tumor may also be resected during this stage.
Hypertrophy Period: A waiting period of approximately four weeks follows, during which the remaining liver is stimulated to grow via portal vein ligation (PVL) or portal vein embolization (PVE).
Second Stage: Once adequate parenchymal hypertrophy is confirmed, a second operation—typically a major or extended hepatectomy—is performed to remove the remaining diseased tissue.
Key Rationale
Safety: Performing the minor resection first protects the FLR by avoiding repeat dissections in a small, friable, hypertrophic remnant later.
Patient Selection: The interval between stages acts as a biological filter. If disease progresses rapidly between stages, the patient is spared the morbidity of a major hepatectomy from which they would not have benefited.
Flexibility: It allows for the integration of conversion chemotherapy to improve resectability.
Preoperative Assessment and Staging
Modern resectability is defined by the ability to achieve an R0 resection (complete removal of all metastatic deposits) while preserving an adequate FLR.
Imaging Modalities
Computed Tomography (CT): Remains the mainstay for assessing intra- and extra-hepatic disease. High-quality studies require multidetector-row CT with thin (2.5 mm) slices and a triple-phase protocol (unenhanced, late arterial, portal venous, and delayed phases).
Magnetic Resonance Imaging (MRI): Essential for patients who have undergone chemotherapy, which reduces CT sensitivity. The combination of Diffusion-Weighted Imaging (DWI) and liver-specific contrast agents (Gd-EOB-DTPA) yields a diagnostic accuracy of 89.2% and is particularly effective at identifying small lesions (<1 cm).
FDG-PET/PET-CT: Reserved for selected cases where conventional modalities provide unclear diagnoses.
Intraoperative Ultrasonography (IOUS)
IOUS is a critical staging tool that often detects nodules missed by preoperative imaging. In a study of 515 patients, IOUS detected new nodules in 25.6% of cases and prompted a change in the surgical plan for 27.2% of patients. Multiple metastases (>3) and bilobar disease are independent predictors for the intraoperative detection of new nodules.
Technical Execution and "Pearls"
First-Stage Surgical Techniques
Parenchymal Sparing: Preference is given to wedge resections and "peeling" metastases off major vessels (vascular R1) rather than anatomical resections, as oncological outcomes are comparable while liver volume is preserved.
No-Clamping Policy: Clamping the hepatic pedicle (Pringle maneuver) is generally avoided to prevent ischemic damage to a liver already sensitized by chemotherapy and to avoid intestinal venous congestion that might jeopardize anastomotic healing.
Portal Vein Ligation (PVL): To stimulate hypertrophy, the right portal branches are ligated.
Ethanol Injection: Injecting 10 ml of absolute alcohol into the right portal vein before ligation reduces the formation of porto-portal venous collaterals and prevents recanalization.
Gallbladder Preservation: The gallbladder should be left in situ during the first stage to reduce postoperative adhesions and facilitate the dissection of the hepatic pedicle during the second stage.
Second-Stage Surgical Techniques
Timing: Volumetry is performed four weeks post-PVO to assess the kinetic of hypertrophy, which typically reaches a plateau by this time.
Glissonian Approach: If dense adhesions from the first stage make pedicle dissection difficult, an intrahepatic suture-ligation or a "Glissonian approach" (using a Mixter clamp to encircle the main sheath) may be employed.
Evaluating Liver Hypertrophy and Safety
Accurate measurement of the FLR is essential to predict the safety of the final major resection.
Volumetry Methods
Standardized Volumetry: Uses a formula based on Body Surface Area (BSA) to estimate total liver volume (eTLV). This method is preferred over direct measurement because it avoids cumulative mathematical errors in patients with multiple lesions and more accurately identifies patients at risk for hepatic insufficiency.
Kinetic Measures:
Degree of Hypertrophy (DH): The percentage-point difference between FLR volume before and after PVO. A cutoff of 5–7.5% is often used.
Kinetic Growth Rate (KGR): Calculated as DH divided by the weeks elapsed since PVO. A KGR >2%/week is a superior predictor of safety, associated with a <10% risk of hepatic insufficiency and 0% mortality from liver failure.
Comparative Analysis of Strategies
Outcomes and Clinical Conclusions
The two-stage approach remains the most reliable strategy for patients with advanced, bilateral CRLM.
Survival: For patients who complete both stages, 3-year survival ranges from 33% to 75%, and 5-year survival is approximately 50% across major series.
The Dropout Phenomenon: Roughly one-quarter of patients fail to reach the second stage. While chemotherapy between stages is sometimes used to prevent progression, data indicates it does not significantly reduce dropout rates.
Interval Growth: Tumor growth in the hemiliver slated for removal during the interval between stages is common (observed in 53% of cases) but is not necessarily a contraindication to the second stage, as it often reflects local growth factors rather than systemic failure.
Ultimately, the success of the two-stage approach depends on rigorous staging, the use of KGR to predict remnant safety, and a "no-clamping" parenchymal-sparing surgical technique.
